BASDAI Shows Best Standardized Response Mean in Real-World Cohort with PsA

Minimally clinically important improvement and standardized response means on patient-reported outcome measures for psoriatic arthritis were small to moderate in a real-world patient population, according to study results published online ahead of print in Arthritis Care & Research.

The longitudinal cohort study included 171 patients who completed several patient-reported outcome measures over a total 266 therapy courses. Researchers calculated mean change in scores between visits and standardized response means. Minimally clinically important improvement was calculated as the mean change in score among patients reporting minimal improvement.

At baseline, the cohort’s average swollen joint count was 3, and the average swollen joint count was 6, according to the study. On all patient-reported outcome measures, standardized response means and minimally clinically important improvement were small to moderate, and greater among patients with higher disease activity at baseline.

The best standardized response mean overall was with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), which was also better for patients with less active psoriatic arthritis, the study found. Best for patients with higher disease activity were the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) and the Psoriatic Arthritis Impact of Disease (PSAID) questionnaire.

“Standardized response means and minimally clinically important improvement were relatively small in this real-world population, particularly among those with lower disease activity at baseline,” wrote Alexis Ogdie, MD, MSCE, of University of Pennsylvania Perelman School of Medicine in Philadelphia, and coauthors. “BASDAI, cDAPSA, and PSAID had good sensitivity to change but selection for use in trials should consider the baseline disease activity of patients to be enrolled.”

—Jolynn Tumolo

Reference
Karmacharya P, Stull C, Stephens-Shields A, et al. Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res. Published online March 13, 2023. doi:10.1002/acr.25111